ESLOY 0MSFT 7.08META -0.85HLPR.TO -0.02VDY.TO 0.38VGG.TO -0.01BIP.UN.TO 0.8TOU.TO -0.5
Abbott Labs (ABT)

NYSE:ABT

Abbott Labs (ABT)

90.42
+2.59 (2.95%)
as of Jun 23, 2026, 8:18:34 pm Market Open.
355 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconJun 23, 2026, 12:00 am

This summary was created by AI, based on 17 opinions in the last 12 months.

Abbott Labs (ABT) has faced a challenging year marked by a significant share price decline of approximately 30%. Analysts note that the company's ability to deliver on its earnings growth target is critical amid increasing competition and recent struggles. Despite these setbacks, several experts maintain a long-term bullish outlook on the company's growth potential, particularly after recent acquisitions that could enhance its position in the oncology space. While the stock is currently priced below its historical valuation, analysts remain cautious due to recent technical breakdowns in its stock chart and ongoing challenges. The company is expected to report quarterly results soon, prompting a wait-and-see approach from some investors, although there is optimism about future growth driven by a stable market for medical devices and diagnostics.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
Bristol-Myers Squibb, BMY
BUY

Abbott Labs(ABT)

Aug 07, 2012

(Market Call Minute.) Broadly diversified healthcare company with proprietary drugs, non-prescription drugs and medical devices. Growing nicely

Photo of David BaskinDavid Baskin
Owned
Unlock Rating
$66.03

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
COMMENT

Abbott Labs(ABT)

Jul 09, 2012
Will be splitting the company into 2 parts, pharma side and medical devices. Purchased a generic company out of India last year and India will be providing health care to the general population but will only pay for generic drugs . Currently within a couple of dollars of her target price so she might shave some of her holdings.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$65.61

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

May 17, 2012
This has been one of the strong companies in the ethical drug companies. Have grown their dividend 10% at year over the last 10 years. Has been a very steady company. Traded sideways for 12 years in a price range and recently in the last year, broke out. They are going to split this company into a medical products/devices company and a pure pharma business. The pharma business will have a high yield attached and the other part has opportunities for efficiencies and growth.
Photo of David BurrowsDavid Burrows
Owned
Unlock Rating
$62.23

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
WAIT

Abbott Labs(ABT)

May 09, 2012
(Market Call Minute.) Splitting in two. Their pharma business is going to be priced more cheaply but be careful because their major drug is 47% of this. To concentrated. He would look at the other piece when they split.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$61.23

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Apr 19, 2012
This is a more of a growth company in the healthcare space. You are looking at higher single-digit growth and you are getting it for around 11-12 times PE. Nice dividend at around 3.4%.
Photo of Stan WongStan Wong
No
Unlock Rating
$59.51

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Abbott Labs(ABT)

Mar 15, 2012
Splitting itself into two businesses – Pharma and Infant nutrition. Couple of interesting acquisitions in the last year and a half. 3.6% yield.
Photo of Gavin GrahamGavin Graham
Owned
Unlock Rating
$59.11

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Feb 09, 2012
Has Merck and Pfizer. There was no time when you could buy it this cheaply except for the August correction.
Photo of Brian Acker, CABrian Acker, CA
No
Unlock Rating
$55.26

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Abbott Labs(ABT)

Nov 29, 2011
Fundamentally he likes it. Operationally it is performing as it should. They are tied into the European economy and people are worried about the EU economies, although their sales are holding up. Getting hurt by tax-loss selling.
Photo of Norman LevineNorman LevineUnlock Rating
$53.05

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
COMMENT

Abbott Labs(ABT)

Oct 24, 2011
Likes health care companies generally because they’re defensive. Splitting their drug company from the rest of the company. Likes this as you get pure plays.
Photo of Norman LevineNorman Levine
No
Unlock Rating
$53.45

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
SELL ON STRENGTH

Abbott Labs(ABT)

Oct 24, 2011
Half of business in Pharma space and rest is in nutritional area.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$53.45

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Oct 20, 2011
Restructuring came as a big surprise. Good valuation at 10X earnings. Long track record of raising dividends. Only real competition is Johnson & Johnson (JNJ-N) but feels this one has better growth. If they do the spinoff, they will probably stick with the non-pharma side of the business, which will be the better growth.
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$54.05

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Abbott Labs(ABT)

Oct 19, 2011
The market likes the split. Going to split into pharma and medical space. 3.6% dividend. Hold on to it for the time being.
Photo of Stan WongStan Wong
No
Unlock Rating
$53.25

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Sep 14, 2011
Diversified Pharma with pharmaceuticals, nutritionals and medical devices. Trading at a lower valuation (11X earnings) with a higher dividend and better growth prospects than Johnson & Johnson (JNJ-N).
Photo of Barry SchwartzBarry Schwartz
Owned
Unlock Rating
$50.92

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
BUY

Abbott Labs(ABT)

Aug 31, 2011
Have grown earnings every single year since 1991. Only 10 or 11x earnings. Likes them in the health care space because they are diversified. Market is worried about their largest drug, whose patent expires in a few years. He doesn’t see it as a problem.
Photo of Gordon ReidGordon Reid
Owned
Unlock Rating
$21.27

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Abbott Labs(ABT)

Aug 02, 2011
(A Top Pick July 26/10. Up 5.72%.) Diversified healthcare company. Branded drug division has Marot for arthritis etc., medical devices including stents and nutritional. Have also been making acquisitions in the branded generic space. Good diversity. About 20% of revenues come from emerging markets.
Photo of Christine PooleChristine Poole
Owned
Unlock Rating
$50.20

Stock price when the opinion was issued

$90.24

As of Jun 23, 2026. Market Open.

biotechnologypharmaceutical
Showing 181 to 195 of 221 entries

You may also like

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

TRI.TO 6.34$114.84
ZTS 0.63$76.52
MSCI 0.1$580.95
NVDA -8.57$200.08
BAC 0.54$57.91

Today's Top Picks

ESLOY 0$96.36
MSFT 7.08$374.42
META -0.85$563
HLPR.TO -0.02$36.38
VDY.TO 0.38$76.2

Popular Articles

Latest Sell Signals

CLS.TO -34.12$499.31
MBGYY 0$12.93
PLTR -3.025$116.475
ATZ.TO -6.21$156.35
AC.TO 0.25$24.2

Most Recent Experts

Paul Harris, CFA

Paul Harris, CFA

Harris Douglas Asset Management

The Panic-Proof Portfolio (Stockchase Research)

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Rob Sechan, Managing Partner, New Edge Capital

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica